Notícias e Atividades da Rebiotix
Executivos
Veja o organograma con seus 7 executivos principais
Biografias mais buscadas da Rebiotix
- Greg Fluet, Chief Operating Officer and Site Head
- Tom Willard, Vice President of Upstream Marketing and Market Strat...
- Lindy Bancke, Head of Clinical Development
Criar um alerta
para seguir os movimentos de executivos da Rebiotix.
Biotecnologia
Rebiotix possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Genus (Reino Unido).
Popular M&A news in Biotecnologia
- Transcarent and Accolade have merged (publicado em 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Rebiotix
- Ferring Receives U.S. FDA Approval for REBYOTA® (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic - Ferring Pharmaceuticals USA
- Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs
- Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic
- Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at IDWeek 2022 - Ferring Pharmaceuticals USA
- Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022 - Ferring Pharmaceuticals USA
- Rebiotix to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
- Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
- Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
- Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
- Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020 - Rebiotix
- View more press releases Close
Redes sociais sobre Rebiotix
- Rebiotix na Wikipedia, Google News e Yahoo Finance
- Rebiotix na LinkedIn, Twitter e YouTube
